Marquette Asset Management LLC bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Rating) during the 2nd quarter, Holdings Channel reports. The fund bought 63,779 shares of the company’s stock, valued at approximately $130,000.
Several other hedge funds also recently modified their holdings of BOLT. Suvretta Capital Management LLC boosted its stake in shares of Bolt Biotherapeutics by 68.3% in the 4th quarter. Suvretta Capital Management LLC now owns 2,230,250 shares of the company’s stock valued at $10,928,000 after purchasing an additional 904,750 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 226.3% in the 1st quarter. Renaissance Technologies LLC now owns 290,100 shares of the company’s stock valued at $795,000 after purchasing an additional 201,200 shares during the last quarter. Echo Street Capital Management LLC bought a new position in shares of Bolt Biotherapeutics in the 1st quarter valued at about $5,493,000. GSA Capital Partners LLP bought a new position in shares of Bolt Biotherapeutics in the 1st quarter valued at about $148,000. Finally, Qube Research & Technologies Ltd boosted its stake in Bolt Biotherapeutics by 204.2% during the 4th quarter. Qube Research & Technologies Ltd now owns 45,640 shares of the company’s stock worth $224,000 after acquiring an additional 30,638 shares during the last quarter. Institutional investors own 69.25% of the company’s stock.
Bolt Biotherapeutics Stock Performance
BOLT stock traded down $0.03 during mid-day trading on Friday, hitting $1.72. 94,084 shares of the company were exchanged, compared to its average volume of 234,240. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.73 and a current ratio of 9.73. The firm’s 50 day simple moving average is $2.08 and its 200 day simple moving average is $2.15. Bolt Biotherapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $14.18.
Insiders Place Their Bets
Wall Street Analyst Weigh In
Separately, SVB Leerink lowered shares of Bolt Biotherapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $8.00 to $4.00 in a research note on Thursday, August 11th.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- Get a free copy of the StockNews.com research report on Bolt Biotherapeutics (BOLT)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.